37 results
6-K
EX-99.1
IPHA
Innate Pharma
21 Mar 24
Summary of Consolidated Financial Statements and Notes
9:20am
agreements over the period. As of December 31, 2023, the deferred revenue related to monalizumab amounts to €5.2 million entirely classified as “Deferred
424B5
IPHA
Innate Pharma
6 Feb 24
Prospectus supplement for primary offering
5:00pm
to be a PFIC. If we are classified as a PFIC for any taxable year during which a U.S. holder holds our ADSs, the U.S. holder may be subject to adverse … of the PFIC rules and the adverse U.S. federal income tax consequences in the event we are classified as a PFIC, see the section of this prospectus supplement
F-3
IPHA
Innate Pharma
20 Dec 23
Shelf registration (foreign)
4:45pm
cause, by a majority stockholder vote, though in the case of a corporation whose board is classified, unless otherwise provided in the certificate
6-K
EX-99.2
iexdo xkgsy
14 Sep 23
Innate Pharma Reports First Half 2023 Financial Results and Business Update
6:27am
6-K
EX-99.1
nvz03thx7nscp8w1
14 Sep 23
Innate Pharma Reports First Half 2023 Financial Results and Business Update
6:27am
6-K
EX-99.1
4j94nw
14 Sep 23
Innate Pharma S.a. 6-K
6:00am
424B5
1co01h
26 Apr 23
Prospectus supplement for primary offering
4:01pm
6-K
EX-99.2
lj0c0v45g6s 0hcd
15 Sep 22
Innate Pharma Reports First Half 2022 Financial Results and Business Update
6:12am
424B5
mku74i2
3 May 22
Prospectus supplement for primary offering
4:36pm
6-K
EX-99.1
s44t80
29 Apr 22
Innate Pharma S.a. 6-K
6:00am
6-K
EX-99.1
t2uppisy dditm
24 Mar 22
Innate Pharma S.a. 6-K
6:00am
6-K
EX-99.1
9jy 5wz5ae68fdba9
17 Sep 21
Monalizumab Data from COAST Trial Presented at ESMO Congress 2021
7:45am
6-K
EX-99.2
w6i7uxjhkln
15 Sep 21
Innate Pharma Reports First Half 2021 Financial Results and Business Update
6:07am
6-K
EX-99.1
xp9d36u1usxd4ii bfgj
18 Mar 21
Innate Pharma Reports Full Year 2020 Financial(1) Results and Business Update
6:30am
F-3
nxosenn7
13 Jan 21
Shelf registration (foreign)
1:59pm